drugset / Trial / NCT04714190
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase III, randomized, multicenter, open-label clinical trial designed to compare RC48-ADC to physician choice standard treatment in participants with human epidermal growth factor receptor 2 (HER2)-overexpression locally advanced or metastatic gastric cancer.
Timeline
- Start
- 2021-03-24
- Primary completion
- 2024-12-01
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Comparator | Irinotecan | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Comparator | Rivoceranib | Small molecule | — | Oral |